Braidwell »

Vor Biopharma shares owned by Braidwell

Quarter-by-quarter ownership of Vor Biopharma (VOR) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Vor Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Vor Biopharma held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vor Biopharma by Braidwell

Quarter filed Position value Share count Share price at filing
2026-03-31 $8.3M 467k 17.84

More positions owned by Braidwell

Caris Life Sciences (CAI)
Guardant Health Debt 1.250% 2/1 (Principal)
Repligen Corp Note 1.000%12/1 (Principal)
Neogenomics Note 0.250% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Glaukos (GKOS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Xenon Pharmaceuticals (XENE)
Dianthus Therapeutics (DNTH)
Edgewise Therapeutics (EWTX)
Irhythm Technologies (IRTC)
Nuvalent Inc-a (NUVL)
Kodiak Sciences (KOD)
Cg Oncology (CGON)
Alphatec Hldgs Note 0.750% 3/1 (Principal)

View all positions for Braidwell

Top funds holding Vor Biopharma

TCG Crossover Management
RA Capital Management
Fcpm Iii Services B.v.
VR Adviser
Frazier Life Sciences Management
FMR
Dr. Jeffrey R. Jay, M.D.
Paradigm Biocapital Advisors
Vanguard Capital Management
Susquehanna International
Caligan Partners
BlackRock
Vanguard Group
Logos Global Management
Boothbay Fund Management

View all funds holding Vor Biopharma